AI drug development company Isomorphic Labs announces completion of a $5 billion Series C financing round led by Greenoaks and Sequoia Capital
Artificial intelligence drug development company Isomorphic Labs announced on November 17, 2026 that it has completed a $5 billion Series C financing round. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz (a16z) and other new investors participating, and Alphabet continuing to make a significant investment; all existing investors (Thrive Capital, MGX, GV, CapitalG, Temasek and the UK sovereign AI fund) also participated in the round.
The company said the funds will be used to advance its proprietary drug design engine (IsoDDE) and AI-designed therapeutic candidate pipeline, deepen foundational biology models, build global AI-driven bioengineering infrastructure, and support the translational and clinical development infrastructure needed to move into clinical trials.
Co-founder and CEO Demis Hassabis said the financing round will accelerate the building of foundational biology models, deepen the understanding of systemic diseases, and drive the first therapeutic programs into clinical trials to have a tangible impact on patients. The company said its models have achieved positive preclinical results in internal oncology and immunology programs and partnership projects, laying the foundation for entry into the clinical stage.
Original source:
Isomorphic Labs official press release (distributed via PR Newswire), “Isomorphic Labs announces $5 Billion Series C funding” (November 17, 2026).
Link: prnewswire.com/news-releases/isomorphic-labs-announces-5-billion-series-c-funding-302942093.html
ABAB AI Insight
Financing structure: This round was an oversubscribed Series C, co-led by the heavyweight Silicon Valley firms Greenoaks and Sequoia, with a16z newly joining, and Alphabet as well as all existing investors following on, reflecting continued capital support.
Use of funds: The company explicitly said the funds will be used to expand the IsoDDE engine, deepen new biology models, build global AI bioengineering infrastructure, and support the translational and clinical development capabilities needed to bring candidate drugs into clinical trials.
Company positioning and progress: Isomorphic Labs focuses on AI-driven new drug design and development; the announcement mentioned positive preclinical results and emphasized accelerating progress toward clinical trials.
Statements and background: CEO Hassabis emphasized using AI to fundamentally accelerate biological understanding and drug discovery; the announcement did not disclose the valuation for this round.
Cognitive law:
When AI drug discovery companies enter the preclinical stage, they often use large financing rounds to strengthen both model capabilities and clinical translation infrastructure at the same time, shortening the path from computational design to human trials